1-800-567-8911 or
604-682-5050
(Telephone interpreting in over 150 languages available)
Trastuzumab deruxtecan
Trade Name:
Enhertu
Manufacturer/Distributor:
AstraZeneca Canada
Classification:
Antineoplastic agent
ATC Class:
L01XC41 - trastuzumab
Status:
active
Notice of Compliance (yyyy/mm/dd):
2021/04/15
Date Marketed in Canada (yyyy/mm/dd):
2021/04/15
Presentation:
Powder for solution 100 mg. DIN: 02514400
Comments:
For treatment of adult patients with HER2-positive breast cancer who have received prior treatment with trastuzumab emtansine.
Back to:
Drug Product Listings 
